NovaDel Pharma's Zolpimist (zolpidem tartrate) 5 mg and 10 mg Oral Spray has been approved by the USFDA for the short-term treatment of insomnia characterized by difficulties with sleep initiation. Zolpimist is NovaDel's second product approved by the FDA that uses NovaDel's proprietary NovaMist oral spray technology. Zolpimist contains zolpidem tartrate, the same active ingredient as Ambien®, the world's leading sedative hypnotic for the treatment of insomnia.
No comments:
Post a Comment